KPVsafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for KPV as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. KPV is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

KPV's small size (342 Da), lack of complex secondary structure, and status as an endogenous cleavage product of α-MSH all contribute to a generally favourable pre-clinical safety profile. In rodent acute toxicity studies, doses many times higher than those producing anti-inflammatory efficacy in colitis models have not produced mortality, organ-weight changes, or histopathological abnormalities in liver, kidney, or spleen. The minimal immunogenicity of a three-amino-acid peptide is expected on theoretical grounds and supported by the absence of antibody induction in studies lasting up to twelve weeks. The main safety consideration specific to KPV concerns the delivery vehicle rather than the peptide itself. Hyaluronic-acid nanoparticles are used in the majority of efficacy studies; the pharmacokinetics, biodistribution, and long-term fate of these carrier systems in vivo require separate evaluation. In Laroui and colleagues' 2013 work, the nanoparticle formulation was well tolerated and showed no apparent intestinal toxicity in DSS-colitis mice, but characterisation of accumulation in secondary organs was limited. Because KPV does not activate MC1R at research-relevant concentrations, systemic melanotropic effects are not expected. However, the potential for supraphysiological stimulation of MC3R and MC5R on immune cells at high injected doses has not been comprehensively characterised. Human safety data for KPV in isolation do not exist. Studies using full-length α-MSH in human endotoxaemia models provide indirect reassurance that the melanocortin anti-inflammatory pathway can be engaged without catastrophic immunosuppression, but direct human KPV pharmacology is unstudied. As with all research peptides, sterility, endotoxin content, and accurate concentration of laboratory preparations represent the most immediate practical safety variables.

UK regulatory status

KPV is not authorised as a medicine by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and does not appear on any current MHRA list of approved active pharmaceutical ingredients for human therapeutic use. It is not a controlled substance under the Misuse of Drugs Act 1971 and does not fall within any specific UK controlled-substance framework. The compound is not named on the World Anti-Doping Agency (WADA) Prohibited List as of the 2025 iteration. Because KPV does not have anabolic, lipolytic, or endocrine-growth properties, it does not fall within the classes most commonly targeted by WADA (S0 non-approved substances, S2 peptide hormones). Researchers should nevertheless verify the current WADA list before conducting studies involving athletes, and note that unlicensed peptides carry inherent contamination-risk under the strict-liability anti-doping framework. In the United Kingdom, possession of KPV for genuine in-vitro laboratory research is unrestricted. Supply or administration to humans as a treatment, or promotion of such use, would engage medicines legislation and require appropriate regulatory authorisation — the specific offences under the Human Medicines Regulations 2012 include supplying, offering to supply, or advertising for supply of an unauthorised medicine to a member of the public. Advertising KPV for inflammatory bowel disease, atopic dermatitis, or any therapeutic indication additionally engages Advertising Standards Authority (ASA) jurisdiction. α-MSH-related compounds (including KPV as an α-MSH tripeptide) have received progressively more MHRA attention as the melanocortin research space has grown; enforcement activity has focused principally on melanotan-family products rather than KPV specifically to date. No known MHRA enforcement actions against KPV specifically have been published. For animal research under the Animals (Scientific Procedures) Act 1986 (ASPA), KPV work in vertebrates requires standard project and personal licences.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. KPV is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full KPV research context including mechanism, study citations, and references, see the main KPV research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.